September 20, 2000Cephradine Capsules
Recalled by Teva Pharmaceuticals
NJ (SafetyAlerts) - The Food and
Drug Administration (FDA) has announced that Teva Pharmaceuticals USA is recalling its
Cephradine Capsules, USP, 500 mg, in 100-count bottles because of subpotency.
This is the first public notice of
this Class II
recall issued by FDA.
Cephradine Capsules, USP, 500 mg, in 100-count bottles, Rx indicated in the
treatment of respiratory tract infections, otitis media, skin and skin-structure
infections, and urinary tract infections. NDC #0093-3155-01.
Lot Numbers 57450 EXP 9/00 and 57988 EXP 6/01.
Teva Pharmaceuticals USA, Fairfield, New Jersey.
Teva Pharmaceuticals USA, Sellersville, Pennsylvania, by letter on August 30, 2000.
Firm-initiated recall ongoing.
10,244 units of lot 057450 and 1,755 units of lot 057988 were distributed; firm estimated
that 5 percent of product remained on market at time of recall initiation.
Safety Alerts compiles
comprehensive safety recall information for the United States. SafeMail is a free email
service to warn consumers of faulty products and contaminated foods. For complete
information regarding current recalls, past recalls and timely product warning
notification visit: www.safetyalerts.com.